W. Schönfeld

发表

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

H. Hawle, M. Fehr, K. Ribi, 2022, Endocrine oncology.

SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer.

B. Thürlimann, H. Hawle, K. Ribi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.